Maximum tolerated medication dose and other predictors of mortality in heart failure with reduced ejection fraction: retrospective cohort study
This study, whilst predating angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter 2 inhibitor use, confirms the importance of achieving maximal tolerated doses of ACEi/ARB and beta-blocker therapy, to maximise associated prognostic benefits in a real-world population. Our findings also highlight the need for continued focus on up-titration of these therapies in the ambulatory setting, and the benefits of a multidisciplinary approach.
Authors
- Daya Ram Parajuli (ORCID: https://orcid.org/0000-0002-9188-8265)
- Sepehr Shakib (ORCID: https://orcid.org/0000-0002-7199-5733)
- Joule J. Li
- Joanne Eng‐Frost (ORCID: https://orcid.org/0000-0002-7526-2078)
- D. Scherer (ORCID: https://orcid.org/0000-0002-7016-7469)
- James Brown
Institutions
- Flinders University (AU)
- Flinders Medical Centre (AU)
- Torrens University Australia (AU)
- Central Adelaide Local Health Network
- The University of Adelaide (AU)
Publication Details
- Journal
- BMC Cardiovascular Disorders
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1186/s12872-025-05104-w
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00